PeptiCrad is conceived to overcome the biggest limitation of the oncolytic vaccine platform e.i. the virus immune-dominance.
In fact, our group and other had demonstrated that the treatment of oncolytic viruses has a dual mode-of-action, the oncolysys (direct lysis of the infected tumor cell) and a "vaccine" effect that occurs triggering some degrees of anti-tumor immune response (Figure below).
Nevertheless the most significant limitation with the naked viruses is that the majority of the immune response is towards the virus and only a small degree of the response is directed towards the tumor.
To overcome this limitation we have developed PeptiCrad, a "virus in tumor's clothing"!
In fact, PeptiCrad is a virus covered with tumor-specific peptides to promote anti-peptides, hence anti-tumor, immune response rather anti-virus immune response.
Compared to naked virus the PeptiCrad technology significantly increase the amount of anti-tumor specific immunity and consequently the overall response.
See dedicated section on publication to have access to the published manuscript.